Table 1 Patient characteristics

Patient number

165

127

38

Age (y), median (range)

42 (20–74)

43 (20–70)

38.5 (21–74)

Male, n (%)

110 (66.7)

79 (62.2)

31 (81.6)

ECOG performance status, n (%)

0

99 (60.0)

82 (64.6)

17 (44.7)

1

64 (38.8)

43 (33.9)

21 (55.3)

Not done

2 (1.2)

2 (1.6)

0

Time from diagnosis to olverembatinib treatment (y), median (range)

5.7 (0.3–23.2)

5.3 (0.6–23.2)

6.9 (0.3–14.7)

Prior TKIs, n (%)

Imatinib

22 (13.3)

16 (12.6)

6 (15.8)

Imatinib/dasatinib

60 (36.4)

47 (37.0)

13 (34.2)

Imatinib/nilotinib

26 (15.8)

22 (17.3)

4 (10.5)

Imatinib/dasatinib/nilotinib

45 (27.3)

35 (27.6)

10 (26.3)

Nilotinib

6 (3.6)

4 (3.1)

2 (5.3)

Dasatinib

2 (1.2)

1 (0.8)

1 (2.6)

Dasatinib/nilotinib

4 (2.4)

2 (1.6)

2 (5.3)

Number of lines of prior TKI therapy, n (%)

1

30 (18.2)

21 (16.5)

9 (23.7)

2

90 (54.5)

71 (55.9)

19 (50.0)

 ≥ 3

45 (27.3)

35 (27.6)

10 (26.3)

BCR-ABL1 mutation status by Sanger sequencing, n (%)

No mutation

24 (14.5)

23 (18.1)

1 (2.6)

T315I single mutation

102 (61.8)

77 (60.6)

25 (65.8)

T315I + additional mutations

25 (15.2)

16 (12.6)

9 (23.7)

Other mutations

14 (8.5)

11 (8.7)

3 (7.9)

BCR-ABL1 mutation status by next-generation sequencing, n (%)

No mutation

20 (16.9)

19 (20.2)

1 (4.2)

T315I single mutation

53 (44.9)

41 (43.6)

12 (50.0)

T315I + additional mutations

19 (16.1)

15 (16.0)

4 (16.7)

Other mutations

14 (11.9)

12 (12.8)

2 (8.3)

Compound mutations

12 (10.2)

7 (7.4)

5 (20.8)

ACA, n (%)

Yes

28 (17.0)

10 (7.9)

18 (47.4)

No

137 (83.0)

117 (92.1)

20 (52.6)